Orchestra BioMed Launches Unpriced Stock Offering to Fund Pivotal Trials
OBIO sits 36% above its 52-week low of $3.46.
Summary
Orchestra BioMed kicked off an underwritten public offering of common stock with no size or price disclosed, and will grant underwriters a 30-day option for up to 15% more shares. Proceeds go to the AVIM Therapy/BACKBEAT pivotal trial and the Virtue SAB program including the Virtue Trial, plus working capital. This is a small-cap (roughly $338M) that burned $23.8M in Q2 on $88K of revenue, so an equity raise was the obvious next step after the $40.9M financing that pushed runway into late 2027. Unpriced overnight deals typically price at a discount to the $4.70 last sale, and dilution is the immediate issue for holders. Piper Sandler and TD Cowen are joint bookrunners with BTIG. Medtronic (MDT) is only the AVIM collaboration partner here and is not a party to the offering.
At the time of this announcement, OBIO was trading at $4.70 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $337.8M. The 52-week trading range was $3.46 to $6.50. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.